dr. mcgregor on challenges facing frontline treatments for rcc
Published 6 years ago • 68 plays • Length 0:53Download video MP4
Download video MP3
Similar videos
-
2:06
dr. mcgregor on whether patients need frontline combinations in rcc
-
1:16
dr. mcgregor on combination therapies with nivolumab, cabozantinib, and sunitinib in rcc
-
1:32
dr. mcgregor on the future of cabozantinib in rcc
-
1:08
dr. mcgregor on unmet needs in non-clear cell rcc
-
1:49
dr. mcgregor on immunotherapy combinations in kidney cancer
-
1:47
dr. mcgregor on choosing a combination therapy regimen in advanced rcc
-
0:57
dr. kaouk on challenges facing surgery for rcc
-
1:22
copy of dr. mcgregor on implications of the fda approval of pembrolizumab/axitinib in rcc
-
4:57
review of the data of frontline treatment for non-clear cell kidney cancer
-
7:52
frontline treatment options for stage 4 rcc
-
0:29
dr. mckay on fda approval of frontline cabozantinib in rcc
-
8:50
comparison of frontline renal cell carcinoma treatment options
-
8:56
frontline treatment approaches in advanced rcc
-
0:59
dr. zibelman on determining treatments for patients with rcc
-
1:33
dr. rini on challenges with biomarkers in rcc
-
1:01
dr. pal on sequencing challenges for the treatment of patients with rcc
-
8:43
optimizing the upfront treatment of metastatic renal cell carcinoma
-
0:53
dr. chowdhury on sequencing of immunotherapy regimens for rcc
-
1:10
dr. motzer on first-line treatment of metastatic rcc